Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: Capecitabine is an attractive oral chemotherapeutic agent that has a radiosensitizing effect and tumor-selectivity. This study was performed to evaluate the efficacy and toxicity of preoperative chemoradiation therapy, when used with oral capecitabine, for locally advanced rectal cancer. Materials and Methods: A prospective phase II trial of preoperative chemoradiation for locally advanced adenocarcinomas of the lower two-thirds of the rectum was conducted. A radiation dose of 50 Gy over five weeks and a daily dose of 1650 mg/m2 capecitabine in two potions was administered during the entire course of radiation therapy. Surgery was performed with standardized total mesorectal excision four to six weeks after completion of the chemoradiation. Results: Between January 2002 and September 2003, 61 patients were enrolled onto this prospective phase II trial. The pretreatment clinical stages were T3 in 64% (n=39), T4 in 36% (n=22) and N1-2 in 82% (n=50) of these patients. Fifty-six (92%) patients completed the chemoradiation as initially planned and a complete resection performed in 58 (95%). Down-staging was observed in 45 patients (74%) and a pathologic complete response in 6 (10%). Among the 37 patients with tumors located within 5 cm from the anal verge on colonoscopy, 27 (73%) underwent a sphincter-preserving procedure. No grade 3 and 4 proctitis or hematological toxicities were observed. Conclusion: Preoperative chemoradiation therapy with capecitabine achieved encouraging rates of tumor down- staging and sphincter preservation, with a low toxicity profile. This combined modality can be regarded as a safe and effective treatment for locally advanced rectal cancer.(Cancer Res Treat. 2004;36:354-359)
참고문헌 (25)
- "Preoperative radiotherapy for resectable rectal cancer:Ameta-analysis", 284, pp.1008~1015 (2000)
- "Radiotherapy inaddition to radical surgery in rectal cancer evidence for adose-response effect favoring preoperative treatment", 37, pp.281~287 (1997)
- "Preoperative 5-FU,low-dose leucovorin,and radiationtherapy for locally advanced and unresectable rectalcancer", 37, pp.289~295 (1997)
- "Tumor downstaging and sphincter preservationwith preoperative chemoradiation in locally advancedrectal cancer: the M. D. Anderson Cancer Center experience", pp.1027~1038 (1999)
- "Prospective trial of preoperative concomitant boostradiotherapy with continuous infusion 5-fluorouracil for locallyadvanced rectal cancer", 47, pp.713~718 (2000)
- "Effective surgical adjuvant therapy forhigh-risk rectal carcinoma", 324, pp.709~15 (1991)
- "Improving adjuvant therapy forrectal cancer by combining protracted-infusion fluorouracil withradiation therapy after curative surgery", 331, pp.502~7 (1994)
- "Adjuvant versus neoadjuvant radiochemotherapy forlocally advanced rectal cancer. A progress report of a phase-IIIrandomized trial (protocol CAO", ARO, pp.2001, 177[DOI]
- "Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report ofintergroup 0114", 20, pp.1744~1750 (2002)
- "Efficacy of intravenous continuousinfusion of fluorouracil compared with bolus administrationin advanced colorectal cancer", 16, pp.301~308 (1998)
- "Patient preferencesfor oral versus intravenous palliative chemotherapy", 15, pp.110~115 (1997)
- "The design and synthesis of a new tumorselectivefluoropyrimidine carbamate, capecitabine", 8, pp.1697~1706 (2000)
- "Preferential activation of capecitabine in tumor followingoral administration to colorectal cancer patients", 45, pp.291~297 (2000)
- "Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluorouracil selectively intumours by enzymes concentrated in human liver and cancertissue", 34, pp.1274~1281 (1998)
- "X-ray irradiation induces thymidine phosphorylase and enhancesthe efficacy of capecitabine (Xeloda) in human cancerxenografts", 5, pp.2948~2953 (1999)
- "Oral capecitabine compared with intravenousfluorouracil plus leucovorin in patients with metastatic colorectalcancer:results of a large phase III study", 19, pp.4097~6 (2001)
- "Comparison of oral capecitabine versus intravenousfluorouracil plus leucovorin as first-line treatment in 605patients with metastatic colorectal cancer:Results of arandomized phase iii study", 19, pp.2282~2292 (2001)
- "Capecitabine asfirst-line treatment in colorectal cancer Pooled data from twolarge, phase III trials", 38, pp.15~20 (2002)
- "Phase I trial evaluating the concurrentcombination of radiotherapy and capecitabine in rectal cancer", 20, pp.3983~3991 (2002)
- "The clinicopathological significance of inferior mesentericlymph node metastasis in colorectal cancer", 30, pp.271~279 (2004)
- "Comparison of 5-fluorouracil pharmacokinetics inpatients receiving continuous 5-fluorouracil infusion and oraluracil plus N1--(2'-tetrahydrofuryl)-5-fluorouracil", 4, pp.2085~2088 (1998)
- "Preoperativechemoradiation using oral capecitabine in locally advancedrectal cancer", 54, pp.403~408 (2002)
- "Combined therapy of locally advancedrectal adenocarcinoma with capecitabine and concurrentradiotherapy", 22, pp.322~ (2003)
- "Capecitabine combined with radiotherapy as neoadjuvanttreatment of locally advanced rectal cancer", 22, pp.277~ (2003)
- "Randomized trial of postoperative adjuvant therapy in stageii and iii rectal cancer to define the optimal sequence ofchemotherapy and radiotherapy:a preliminary report", 20, pp.1751~1758 (2002)